HC Wainwright Brokers Increase Earnings Estimates for DBVT

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for DBV Technologies in a report released on Monday, May 5th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.85) per share for the year, up from their previous forecast of ($5.55). HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies' FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.37) EPS.

DBVT has been the subject of a number of other research reports. JMP Securities raised their price target on shares of DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a research note on Thursday, May 1st. StockNews.com upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research report on Friday.

DBV Technologies Price Performance

Shares of DBV Technologies stock traded down $0.01 during trading on Wednesday, hitting $9.83. 64,403 shares of the company's stock traded hands, compared to its average volume of 185,684. The company has a market cap of $269.24 million, a PE ratio of -2.18 and a beta of -0.66. The firm's fifty day moving average price is $6.91 and its 200 day moving average price is $4.87. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $10.12.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The firm had revenue of $0.51 million during the quarter.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.